Clearside Biomedical Inc

Clearside Biomedical — Investor Presentation (April 2020)

32 slides from Clearside Biomedical's investor presentation, Apr 8, 2020

  1. Slide 1: Corporate Presentation | April 2020

    Corporate Presentation | April 2020 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  3. Slide 3: Versatile Therapeutic Platform

    Versatile Therapeutic Platform SCS Microinjector™ with proprietary drug formulations target the Suprachoroidal Space Proprietary Access to the Suprachoroidal Space (SCS®) Utilization Across Small Molecules and Gene Therapy Ability to Target Multiple Ocular Diseases Internal Research & Development Pi

  4. Slide 4: Evolution of Injection Procedures to Reach the Back of the Eye

    Evolution of Injection Procedures to Reach the Back of the Eye Intravitreal Injection Broad diffusion to all areas of the eye including the anterior chamber and lens Highly variable drug diffusion across the sclera into the eye Periocular Injection Subretinal Injection Invasive surgery with variable

  5. Slide 5: Exclusive Access to the Back of the Eye Using Proprietary SCS Microinjector

    © 2019 Clearside Biomedical, Inc. Exclusive Access to the Back of the Eye Using Clearside’s Proprietary SCS Microinjector™

  6. Slide 6: Core Advantages of Treating Via the Suprachoroidal Space

    Core Advantages of Treating Via the Suprachoroidal Space Sources: PK = pharmacokinetic | Rai UDJ, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495. | Moisseiev E, Loewenstein A, Yiu G. The suprachor

  7. Slide 7: Preclinical Data Leads to Clinical Results

    Preclinical Data Leads to Clinical Results Sources: Gilger, et al, Treatment of Acute Posterior Uveitis in a Porcine Model by Injection of Triamcinolone Acetonide into the Suprachoroidal Space Using Microneedles, Physiology and Pharmacology | Edelhauser HF, et al. ARVO Annual Meeting. 2013 | XIPERE

  8. Slide 8: Pipeline of SCS Treatments with Broad Applicability

    STUDY DRUG INDICATION CLS-AX (axitinib injectable suspension) Wet AMD Gene Therapy Inherited Retinal Disease Pipeline of SCS Treatments with Broad Applicability PRECLINICAL IND-Enabling PHASE 1/2 PHASE 3 NDA PARTNER INDICATION BAUSCH HEALTH Macular edema associated with uveitis (XIPERE™) ARCTIC VISI

  9. Slide 9: Internal Pipeline Opportunities

    Internal Pipeline Opportunities

  10. Slide 10: Axitinib for Suprachoroidal Injection (CLS-AX): A Potential Solution for Treatment Burden

    The Opportunity Reduce patient burden from monthly injections to every six months or longer Pan-VEGF inhibition potentially more efficacious than current approaches Improve long-term, real-world visual outcomes for patients Provide physicians with ability to titrate dose based on patient need Protec

  11. Slide 11: Sources

    Sources: 1. Heier JS et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-2548. | 2. Brown DM et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR s

  12. Slide 12: Suprachoroidal Axitinib May Improve Outcomes with Broad VEGF Receptor Blockade

    AMD Vascular Endothelial Growth Factor Treatment Approaches Anti-VEGF-A increases expression of VEGF-C 1 VEGF-D2 Broad VEGF receptor blockade may improve outcomes A Phase 2 study yielded better AMD outcomes with anti-VEGF-A,C,D vs anti-VEGF-A Current AMD Therapies Predominantly Focus on Binding VEGF

  13. Slide 13: CLS-AX: High Drug Levels Maintained in the Retina after SCS administration

    Concentration (nM) CLS-AX: High Drug Levels Maintained in the Retina after SCS administration High Retina Levels: Sufficient to block VEGF pathway Low Plasma Levels: <1 ng/mL Time (days) Source: Based on Clearside Biomedical non-clinical data

  14. Slide 14: Topical Axitinib More Effectively Inhibited Murine Corneal Neovascularization

    Topical Axitinib More Effectively Inhibited Experimental Murine Corneal Neovascularization than Sunitinib and Sorafenib (same dose) Source: Yuan et al. Ocular Drug Delivery Nanowafer with Enhanced Therapeutic Efficacy. ACS Nano. 24 Feb 2015;9(2):1749-58

  15. Slide 15: Potential to Disrupt the AMD Treatment Landscape

    Broad VEGF Blockade Focused VEGF Blockade Ceiling of efficacy Treatment burden Limited outcomes Short Acting (1-3 months) CURRENT THERAPY CLS-AX (SCS) Targeted for efficacy Bioavailable with prolonged PK or durability Long Acting (>6 months) Compartmentalized for safety Potential to Disrupt the AMD

  16. Slide 16: Exploratory Preclinical PK Study: Complement Inhibitor and the Suprachoroidal Space

    Exploratory Preclinical PK Study Complement Inhibitor and the Suprachoroidal Space Suprachoroidal delivery of complement inhibitor small molecule suspension resulted in targeted, compartmentalized, and sustained ocular levels in rabbits Targeted & Compartmentalized: High exposure for 90+ days in RPE

  17. Slide 17: Broad Applicability of SCS Injection Platform: Ocular Gene Therapy

    The Opportunity Avoid risks of vitrectomy (surgery) Avoid risks of retinotomy, subretinal injection, and macular detachment Deliver larger genes using non-viral vectors Convert gene therapy into an office-based procedure Potential for broader retinal coverage Enhance patient access Primary Need Targ

  18. Slide 18: SCS Injections of DNA Nanoparticles May Offer Safe and Efficient Delivery

    Preclinical Studies Demonstrate SCS Injections of DNA nanoparticles (DNPs) May Offer the Potential for a Safe and Efficient Delivery Method Potential Advantages Efficacy: demonstrated in numerous ocular animal models Transfer large genes (up to ~20 kb) Safety: Non-immunogenic, without viral capsid p

  19. Slide 19: Preclinical SCS and Subretinal DNA Nanoparticle Injections Produced Comparable Luciferase Activity

    Preclinical SCS and Subretinal Injections of DNA Nanoparticles Produced Comparable Luciferase Activity Source: Szilárd Kiss, MD, Macula Society Presentation February 2019 CHOROID-RPE-Sclera Non-Viral Luciferase, Rabbit RETINA Non-Viral Luciferase, Rabbit DNA Nanoparticles Transfect Choroid and Reti

  20. Slide 20: Published Preclinical Data on Viral Vectors in SCS

    Published Preclinical Data on Viral Vectors in SCS Source: Ding, K., Shen, J., Hafiz, Z., Hackett, S. F., Silva, R. L. E., Khan, M., ... Campochiaro, P. A. (2019). AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. Journal of Clinical Investigation. doi: 10.1

  21. Slide 21: Corporate Collaborations

    Corporate Collaborations & SLEARSIDE

  22. Slide 22: Enabling In-office Delivery of Gene Therapy for Retinal Disease

    The Opportunity: Gene Therapy Exclusive worldwide rights to our SCS Microinjector for delivery of adeno-associated virus (AAV)-based therapeutics to the suprachoroidal space to treat wet AMD, diabetic retinopathy and other conditions for which anti-VEGF treatment is the standard of care Delivery of

  23. Slide 23: REGENXBIO Initiating Two Phase 2 Trials

    RGX-314 for Treatment of Wet Age-Related Macular Degeneration (AMD) REGENXBIO plans to initiate Phase 2 trial of suprachoroidal delivery of RGX-314 using SCS Microinjector™ for treatment of wet AMD in first half of 2020. Trial will build upon data from Phase 1/2a trial of RGX-314 and is expected to

  24. Slide 24: Optimizing Ocular Oncology Drug Delivery with SCS Microinjector

    The Opportunity: Ocular Oncology Non-surgical alternative to intravitreal delivery of Aura’s oncology drug candidates via our SCS Microinjector Choroidal melanoma is the most common, primary intraocular tumor in adults Expect Aura to initiate clinical testing using our SCS Microinjector in the secon

  25. Slide 25: Novel Approach to Targeting Uveitic Macular Edema Using SCS Microinjector

    Macular edema is the leading cause of vision loss in patients with non-infectious uveitis Pivotal Phase 3 PEACHTREE trial met its primary endpoint MAGNOLIA Phase 3 extension study demonstrated durability If approved, XIPERE would be the first therapy for this indication Expect to resubmit NDA with t

  26. Slide 26: Maximizing Commercial Potential of XIPERE (U.S. and Canada)

    The Opportunity: XIPERE Commercialization & Development Exclusive license for XIPERE commercialization and development in the U.S. and Canada Right to develop and commercialize XIPERE for additional ophthalmic indications including diabetic macular edema and retinal vein occlusion Right to develop a

  27. Slide 27: Maximizing Commercial Potential of XIPERE (Greater China and South Korea)

    The Opportunity: XIPERE Commercialization & Development in Greater China and South Korea Exclusive license to develop and commercialize XIPERE for indications associated with uveitis in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea Right to develop and commercialize XIP

  28. Slide 28: Three Partnering Deals to Drive Growth

    1 2 3 4 Eliminated the inherent risks and financial investment related to building and maintaining a commercial infrastructure Validated our investment in suprachoroidal delivery using our SCS Microinjector Expanded our overall internal and collaborative product development pipeline Eligible to rece

  29. Slide 29: Strong Intellectual Property Coverage of SCS Platform

    19 Apparatus using loss-of-resistance technology Administration of any anti-inflammatory drug to the suprachoroidal space by microinjection Methods of treating posterior ocular disorders including macular edema or uveitis Methods using loss-of-resistance technology Apparatus having / methods using a

  30. Slide 30: Experienced Leadership Team

    GEORGE LASEZKAY Pharm.D., J.D. | CEO and Director 30 years experience Allergan, Acucela, Novagali, Amakem, RetroSense THOMAS CIULLA M.D., MBA | Chief Medical Officer 27 years experience Spark Therapeutics, Ophthotech, Indiana University School of Medicine CHARLES DEIGNAN Chief Financial Officer 27 y

  31. Slide 31: Research and Development Investment Highlights

    Research and Development Investment Highlights *REGENXBIO (RGNX) trials involve suprachoroidal delivery of RGX-314 using the SCS Microinjector. | ^Aura trials involve suprachoroidal delivery of AU-011 using the SCS Microinjector Versatile therapeutic platform with proprietary access to the suprachor

  32. Slide 32: UM Bane |

    UM Bane |

Clearside Biomedical — Investor Presentation (April 2020) on 6ix